STAT+: Pharmalittle: We’re reading about a GSK vaccine deal, an Alzheimer’s drug approval, and more
GSK reached a licensing agreement with mRNA-vaccine developer CureVac worth up to $1.8 billion to develop its vaccines for seasonal flu, Covid-19, and avian flu.
Top of the morning to you, and a fine one it is. The skies are clear, the sun is shining, and all sorts of birds are chirping outside our window. Moreover, there is
